risks of glp-1 Agonists In Obesity Mapping the effectiveness and risks

Exploratory analyses found no meaningful differences in effect between participants with baseline BPs above versus below the cohort median baseline BP or between those with controlled versus uncontrolled hypertension

"Trump Says Obesity Drugmakers Will Cut GLP-1 PricesMedicare Will Cover Some Costs"

For current practice, the most defensible use of GLP-1RAs is as a time-bounded metabolic optimization strategy in women with meaningful obesity/insulin-resistance burden, with reproductive endpoints interpreted as potential downstream gains rather than guaranteed direct effects (111, 112, 124)

6, A399A400

Between January 1, 2022 and April 24, 2023 Scripius (approximately 1 million members) identified $6.1 million in GLP-1 claims that had the potential for FWA